Your browser doesn't support javascript.
loading
Imatinib­induced gynecomastia: A case report.
Li, Xiao-Lan; Li, Min; Tu, Sheng-Ke; Fan, Hong-Jie; Shi, Zi-Wei; Wang, Ling-Zhi; Tian, Juan; Song, Kui.
Afiliación
  • Li XL; Department of Hematology, The First Affiliated Hospital of Jishou University, Jishou, Hunan 416000, P.R. China.
  • Li M; Department of Pharmacy, The First Affiliated Hospital of Jishou University, Jishou, Hunan 416000, P.R. China.
  • Tu SK; Department of Hematology, The First Affiliated Hospital of Jishou University, Jishou, Hunan 416000, P.R. China.
  • Fan HJ; Department of Hematology, The First Affiliated Hospital of Jishou University, Jishou, Hunan 416000, P.R. China.
  • Shi ZW; Department of Hematology, The First Affiliated Hospital of Jishou University, Jishou, Hunan 416000, P.R. China.
  • Wang LZ; Department of Pharmacy, The First Affiliated Hospital of Jishou University, Jishou, Hunan 416000, P.R. China.
  • Tian J; Department of Hematology, The First Affiliated Hospital of Jishou University, Jishou, Hunan 416000, P.R. China.
  • Song K; Department of Hematology, The First Affiliated Hospital of Jishou University, Jishou, Hunan 416000, P.R. China.
Exp Ther Med ; 28(5): 425, 2024 Nov.
Article en En | MEDLINE | ID: mdl-39301253
ABSTRACT
Chronic myeloid leukemia is a myeloproliferative neoplasm characterized by the unregulated and abnormal proliferation of both mature and immature granulocytes, which results in the proliferation of peripheral blood leukocytes. Imatinib, a tyrosine kinase inhibitor, is the first-line treatment for patients diagnosed with chronic myeloid leukemia. However, despite its favorable safety profile, imatinib use is associated with a number of side effects. Gynecomastia is a rare adverse effect of imatinib treatment and may be associated with an imbalance in sex hormones. The present study reports the case of a patient with chronic myeloid leukemia diagnosed with gynecomastia after imatinib treatment. The aim of the present report was to highlight to clinicians this adverse reaction to imatinib treatment and investigate a treatment strategy with fewer side effects.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Exp Ther Med Año: 2024 Tipo del documento: Article Pais de publicación: Grecia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Exp Ther Med Año: 2024 Tipo del documento: Article Pais de publicación: Grecia